Company Encyclopedia
View More
name
XTL BioPharma
XTLB.US
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren’s syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd.
1.946 T
XTLB.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking322/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-26.83%E
    • Profit Margin-227.72%E
    • Gross Margin0.67%E
  • Growth ScoreC
    • Revenue YoY0.00%C
    • Net Profit YoY42.37%B
    • Total Assets YoY252.43%A
    • Net Assets YoY144.82%A
  • Cash ScoreD
    • Cash Flow Margin-43.91%D
    • OCF YoY0.00%C
  • Operating ScoreE
    • Turnover0.08E
  • Debt ScoreB
    • Gearing Ratio36.43%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    XTL Biopharmaceuticals Announces Board Changes Following Resignation

    XTL Biopharmaceuticals announced board changes following the resignation of Doron Turjeman from the Board of Directors on October 21, 2025. Noam Band, the CEO, has been appointed to the board. Spark's analysis indicates that XTLB is underperforming, citing financial difficulties and a bearish outlook despite a recent stock price surge. The company, which owns The Social Proxy Ltd. and has an IP portfolio for Lupus treatment, is publicly traded on Nasdaq and the Tel Aviv Stock Exchange, with a current market cap of $11.73M.

    Tip Ranks·
    US
    XTLB
    +3.96%
    Tip Ranks·
    US
    XTLB
    +3.96%

    XTL Biopharmaceuticals Appoints CEO Noam Band to Board as Doron Turjeman Resigns

    XTL Biopharmaceuticals Ltd. has announced the resignation of Doron Turjeman from the Board of Directors, effective October 21, 2025, due to personal reasons. Noam Band, the current CEO, has been appointed to the Board immediately following this change.

    Reuters·
    US
    XTLB
    +3.96%
    Reuters·
    US
    XTLB
    +3.96%

    U.S. stock night trading anomaly: XTL BioPharma rose 3.68% in night trading

    XTL BioPharma rose 3.68% in after-hours trading; Recursion Pharmaceuticals rose 1.52% in after-hours trading, with a transaction volume of USD 146,100; Moderna rose 0.11% in after-hours trading, with a transaction volume of USD 106,900; CRISPR Therapeutics rose 0.77% in after-hours trading, with a transaction volume of USD 98,200

    Tracking Unusual Activity·
    US
    XTLB
    +3.96%
    Tracking Unusual Activity·
    US
    XTLB
    +3.96%

    12 Health Care Stocks Moving In Wednesday's Intraday Session

    In Wednesday's intraday session, several health care stocks saw significant movements. Xenetic Biosciences (NASDAQ: XBIO) surged 137.1% to $10.17, with a market cap of $6.6 million. AlphaTON Capital (NASDAQ: ATON) rose 80.66% to $10.08, valued at $33.6 million. Nexalin Technology (NASDAQ: NXL) increased 75.86% to $1.65, with a market cap of $16.3 million. Acurx Pharmaceuticals (NASDAQ: ACXP) gained 69.46% to $7.27, valued at $6.7 million. XTL Biopharmaceuticals (NASDAQ: XTLB) rose 55.0% to $2.17, with a market cap of $12.3 million. Universe Pharmaceuticals (NASDAQ: UPC) increased 52.56% to $7.89, valued at $78.7 million.

    Benzinga·
    US
    XBIO
    +4.96%
    US
    XTLB
    +3.96%
    US
    ACXP
    +6.10%
    Benzinga·
    US
    XBIO
    +4.96%
    US
    XTLB
    +3.96%
    US
    ACXP
    +6.10%

    12 Health Care Stocks Moving In Wednesday's Pre-Market Session

    In Wednesday's pre-market session, several health care stocks saw significant movements. Xenetic Biosciences (NASDAQ: XBIO) surged by 212.3% to $13.4, with a market cap of $6.6 million. AlphaTON Capital (NASDAQ: ATON) rose by 168.99% to $15.01, market cap at $33.6 million. Acurx Pharmaceuticals (NASDAQ: ACXP) increased by 88.81% to $8.1, market cap at $6.7 million. Other notable gainers included XTL Biopharmaceuticals (NASDAQ: XTLB) up 75.71%, TransCode Therapeutics (NASDAQ: RNAZ) up 74.78%, and Universe Pharmaceuticals (NASDAQ: UPC) up 73.69%.

    Benzinga·
    US
    XBIO
    +4.96%
    US
    XTLB
    +3.96%
    US
    ACXP
    +6.10%
    Benzinga·
    US
    XBIO
    +4.96%
    US
    XTLB
    +3.96%
    US
    ACXP
    +6.10%
    © 2025 Longbridge｜Disclaimer